Abdi Ibrahim Pharmaceuticals forms a joint venture with Cigalah Healthcare, laying the foundation for expansion into Saudi Arabia and beyond, prioritizing exports as the initial step.
Through the partnership with Cigalah Healthcare, a leading pharmaceutical and consumer health company in Saudi Arabia and the Gulf region, Abdi Ibrahim’s innovative medicines will be exported to countries in the region, starting with Saudi Arabia.
Abdi Ibrahim Chairman Nezih Barut said, ” This joint venture fills us with pride as we bring innovative medicines to the Saudi people and bolster our nation’s economy through exports. Anticipating the beginning of a success story, our journey starts in the Saudi market, with plans to expand throughout the Gulf region. We aspire for this narrative to serve as a pivotal model for economic cooperation between Türkiye and Saudi Arabia. Teaming up with two illustrious companies with centuries-old legacies, we are committed to achieving success through diligent effort.”
“Abdi Cigalah Pharma,” a joint venture entity established with a 50 percent stake held by Cigalah Healthcare, a prominent entity in Saudi Arabia and the Gulf region’s pharmaceutical and consumer health sectors, was unveiled during a signing ceremony in Jeddah, Saudi Arabia on April 29.
Abdi Ibrahim Chairman Nezih Barut, Abdi Ibrahim CEO Dr. Süha Taşpolatoğlu, and Cigalah Healthcare Chairman Yaser Naghi attended the partnership signing ceremony. This alliance is poised to facilitate Abdi İbrahim’s robust entry into the Gulf region, identified as a strategic priority.
Cigalah Healthcare Chairman and CEO Yaser Naghi remarked: “Our strategic collaboration with Abdi Ibrahim reinforces our commitment to elevating healthcare standards across the region. By leveraging the strengths of both organizations and fostering cooperation in areas such as research and development, manufacturing, and marketing, the joint venture will facilitate market access, promote quality healthcare, stimulate economic growth, foster bilateral partnerships, and contribute to the advancement of the pharmaceutical industry in the Middle East.”
